Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alkermes

- PMLiVE

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Target action date for FDA decision is due on 15 November

- PMLiVE

Troubled Alkermes eyes November OK for new antipsychotic

Review begins for potential schizophrenia and bipolar I disorder drug

- PMLiVE

Intra-Cellular soars on FDA approval of schizophrenia drug

Shares rocketed following the announcement

- PMLiVE

Karuna’s shares spike on schizophrenia drug data

Value leaps to more than $1bn following mid-stage trial results

- PMLiVE

Alkermes boosts CNS presence with $950m Rodin acquisition

Follows company making job cuts in September as part of cost-saving efforts

Biogen Idec building

FDA starts review of Biogen’s Tecfidera follow-up for MS

It was initally submitted towards the end of 2018 but had been delayed by US gov shutdown

- PMLiVE

Indivior push to diversify boosted by schizophrenia drug approval

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

- PMLiVE

Alkermes slumps as FDA turns down depression drug

The drug needs to be supported with additional trials and a bioavailability study, says US regulator

Biogen Idec building

Biogen pays $590m for Pfizer cognition drug

Early stage studies look positive for schizophrenia drug

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

- PMLiVE

Boehringer abandons PDE-targeted Alzheimer’s drug

But will keep testing the candidate in schizophrenia

Boehringer Ingelheim headquarters

Boehringer adds to pipeline again with €628m Autifony CNS deal

Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links